Short Interest in Valneva SE (NASDAQ:VALN) Declines By 34.6%

Valneva SE (NASDAQ:VALN - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 15,900 shares, a drop of 34.6% from the December 15th total of 24,300 shares. Approximately 0.0% of the company's stock are sold short. Based on an average daily volume of 38,300 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their target price on shares of Valneva from $23.00 to $20.00 and set a "buy" rating for the company in a report on Friday, October 11th.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC grew its stake in Valneva SE (NASDAQ:VALN - Free Report) by 33.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,000 shares of the company's stock after purchasing an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Price Performance

NASDAQ:VALN traded down $0.05 during trading hours on Tuesday, hitting $4.39. The company's stock had a trading volume of 53,541 shares, compared to its average volume of 44,080. The stock has a fifty day simple moving average of $4.38 and a 200-day simple moving average of $5.91. The company has a market capitalization of $356.74 million, a P/E ratio of -33.77 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.